Core Viewpoint - The company has obtained a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting Newcastle disease, avian influenza (H9 subtype), and avian adenovirus disease (I group 4) [1] Group 1: Regulatory Compliance - The vaccine registration is in accordance with the Veterinary Drug Management Regulations and the Measures for the Approval Number Management of Veterinary Drug Products [1] - The company is currently in the process of applying for the veterinary product approval number issued by the Ministry of Agriculture and Rural Affairs, which is required before the product can be marketed [1]

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - The company, Blue Biological (603739), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Oxidized Amine Iodine Solution," which is classified as a Class III new veterinary drug and is intended for disinfection in farming environments [1] Group 1 - The approval includes a registration certificate for the new veterinary drug [1] - The new product is developed in collaboration with the company's wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., and other units [1]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-055 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛康 地恩动物药业有限公司与其他单位联合申报的"氧化胺碘溶液"为三类新兽药， 并于近日核发了《新兽药注册证书》（农业农村部公告第 970 号）。 新兽药名称：氧化胺碘溶液 研制单位：青岛农业大学、青岛蔚蓝生物股份有限公司、云南农业大学、四 川瑞芳德生物制药有限责任公司、成都科宏达科技有限公司、青岛康地恩动物药 业有限公司、山东康益健生物科技有限公司、河北金元康药业有限公司、大理金 明动物药业有限公司、青岛元成生物科技有限公司、安徽中龙国创生物科技有限 公司、江西派尼生物药业有限公司、济南百鸣生物制药有限公司、海南育奇药业 有限公司。 主要成分：碘 作用与用途：用于厩舍的消毒。 用法与用量：以本品计。喷雾：厩舍地面、墙面、食槽的 ...

Core Viewpoint - The company, Blue Biological (603739), has received approval for its new veterinary drug "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, with the issuance of the "New Veterinary Drug Registration Certificate" [1] Group 1 - The company and its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., jointly applied for the approval of the new veterinary drug [1] - The approval signifies a significant milestone for the company in expanding its product offerings in the veterinary medicine sector [1]

Core Viewpoint - The company, Weilan Bio (603739.SH), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Oxidized Amine Iodine Solution," which is classified as a Class III new veterinary drug and is intended for disinfection in breeding environments [1]. Group 1 - The approval was granted based on the review of relevant regulations, including the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1]. - The new veterinary drug registration certificate was issued recently, as indicated by the Ministry of Agriculture and Rural Affairs announcement No. 970 [1]. - The product is developed by the company and its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., in collaboration with other entities [1].

Core Viewpoint - The company, Blue Biological (603739.SH), announced that its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., along with other units, has received approval for "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, and has recently been issued a "New Veterinary Drug Registration Certificate" [1] Company Summary - Blue Biological has successfully obtained regulatory approval for a new veterinary drug, indicating progress in its product development pipeline [1] - The approval of the new veterinary drug may enhance the company's market position and expand its product offerings in the veterinary pharmaceutical sector [1] Industry Summary - The approval of new veterinary drugs is significant for the industry, as it reflects ongoing innovation and regulatory compliance within the veterinary pharmaceutical market [1] - The introduction of Class III new veterinary drugs can potentially lead to increased competition and improved animal health solutions in the market [1]

Core Viewpoint - The company is actively expanding its pet health product line, with a long-term product planning scheme that includes chemical drugs, biological products, and pet health products [1] Group 1: Product Development - The company is focusing on self-branded production and sales of pet health products, without engaging in OEM business [1] - A comprehensive R&D and market operation team will be gradually established to support product promotion [1] Group 2: Market Strategy - The company plans to develop distribution channels primarily through offline veterinary hospitals [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations, ensuring timely announcements of relevant information [1]

Core Viewpoint - The company, Weilan Bio (603739), is currently in the early stages of developing synthetic biology products, with significant challenges ahead in terms of commercialization and industrialization [1] Group 1: Research and Development - The company has established a synthetic biology and biocatalysis technology center, which includes an innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] - The current R&D projects in the synthetic biology technology innovation laboratory are limited, with low investment amounts and insufficient professional personnel [1] - The laboratory is still in the preliminary strain research phase, indicating a considerable gap before achieving large-scale production [1] Group 2: Production Challenges - The production of synthetic biology products involves complex processes such as separation and purification, which the company currently lacks the capability to perform [1] - There are significant uncertainties regarding the commercialization of these products, which may also require regulatory approvals and market promotion, leading to a lengthy and challenging process [1] Group 3: Impact on Operations - The company anticipates that the current developments in synthetic biology will not have a significant impact on its operations in the foreseeable future [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations and will provide timely updates through official announcements [1]